Abstract
Drugs evaluation has been undergoing a transformational shift from the classical sequence of randomized control trials (RCT) and Real-World (RW) studies towards a more agile process capitalizing better and faster from retrospective data. The purpose of this work is to propose a regulatory-grade, data-integrative, real-world-value-based and disease-centric approach to accelerate and de-risk drugs development and launch. This approach relies on disease and care modeling on the pre-competitive space and federated data sourcing.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
